For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the introduction of Vyndamax and Tafamidis meglumine represents a significant advancement . These groundbreaking therapies preserve the transthyretin protein, halting its destructive build-up and alleviating the severity of the illness. People are now s